News
Eli Lilly and Company received FDA approval for Cymbalta
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain and...
News
Eli Lilly to Open a Diabetes-Focused Research Center in China
Eli Lilly and Company announced plans to open a research center focused on diabetes in China, where the incidence of the disease has reached epidemic proportions. The center, to open in Shanghai in the second half of 2011, will...
News
GlaxoSmithKline receives approval in Japan from the Ministry of Health
GlaxoSmithKline announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag) for the treatment of the blood disorder, chronic idiopathic thrombocytopenic purpura (ITP), and for Xyzal (levocetirizine dihydrochloride), the first...
News
Dako and Quintiles form alliance to speed development of personalized medicine
Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Quintiles, the world’s leading bio pharmaceutical services companies, announced a strategic alliance to advance personalized medicine by collaborating on the co-development of targeted therapies and companion diagnostics. ...
News
Pfizer’s Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
Pfizer Inc announced today that the Japanese Ministry of Health, Labour and Welfare approved Lyrica® (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment...
News
PRADAX gains approval in Canada for stroke prevention in atrial fibrillation
Health Canada, the Canadian health authority, has approved PRADAX™ (dabigatran etexilate), 1 Boehringer Ingelheim’s novel, oral direct thrombin inhibitor 2 for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) in whom anticoagulation is appropriate,...
News
Significant Milestone for Tengion Clinical Program Currently Enrolling Bladder Cancer Patients
Tengion, Inc., a leader in regenerative medicine, announced that surgeons at the University of Chicago have implanted its Neo-Urinary Conduit(TM) in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read